Alkalinization
Analgesics..
Antiandrogens..
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Lifestyle..
Melatonin
Metformin
Molnupiravir
Monoclonals..
Nigella Sativa
Nitazoxanide
Nitric Oxide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Quercetin
Remdesivir
Vitamins..
Zinc

Other
Feedback
Home
Home   COVID-19 treatment studies for Hydroxychloroquine  COVID-19 treatment studies for HCQ  C19 studies: HCQ  HCQ   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent:  
0 0.5 1 1.5 2+ Intubation/hospitalization 55% Improvement Relative Risk c19hcq.org Davido et al. HCQ for COVID-19 LATE TREATMENT Is late treatment with HCQ beneficial for COVID-19? Retrospective 132 patients in France Lower intubation/hosp. with HCQ (p=0.04) Davido et al., Int. J. Antimicrobial Agents, 2020, doi:10.1016/j.ijantimicag.2020.106129 Favors HCQ Favors control
Impact of medical care including anti-infective agents use on the prognosis of COVID-19 hospitalized patients over time
Davido et al., Int. J. Antimicrobial Agents, 2020, doi:10.1016/j.ijantimicag.2020.106129
Davido et al., Impact of medical care including anti-infective agents use on the prognosis of COVID-19 hospitalized patients.., Int. J. Antimicrobial Agents, 2020, doi:10.1016/j.ijantimicag.2020.106129
Aug 2020   Source   PDF  
  Twitter
  Facebook
Share
  All Studies   Meta
Retrospective of 132 hospitalized patients. HCQ+AZ(52)/AZ(28) significantly reduced death/ICU, HR=0.45, p=0.04. Adjusted for Charlson Comorbidity Index (including age), obesity, O2, lymphocyte count, and treatments. Mean delay from admission to treatment 0.7 days.
risk of intubation/hospitalization, 55.0% lower, HR 0.45, p = 0.04, treatment 12 of 80 (15.0%), control 13 of 40 (32.5%), NNT 5.7.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Davido et al., 2 Aug 2020, retrospective, France, peer-reviewed, 14 authors.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperHCQAll
Abstract: Version of Record: https://www.sciencedirect.com/science/article/pii/S0924857920303125 Manuscript_8414355259043bebf7cba1d22abeb157 1 Impact of medical care including anti-infective agents use on the prognosis of 2 COVID-19 hospitalized patients over time 3 Benjamin Davido1, Ghilas Boussaid2, Isabelle Vaugier3, Thibaud Lansaman4, 4 Frédérique Bouchand5, Christine Lawrence6, Jean-Claude Alvarez7, Pierre Moine8, 5 Véronique Perronne1, Frédéric Barbot3, Azzam Saleh-Mghir1, Christian Perronne1, 6 Djillali Annane8, Pierre De Truchis1, on behalf of the COVID-19 RPC Team* 7 1 8 Garches, France 9 2 Université Paris-Saclay, UVSQ, Erphan, 78000, Versailles, France. 10 3 Centre d’Investigation Clinique (Inserm CIC 1429), Université Paris-Saclay, AP-HP 11 Hôpital Raymond Poincaré, Garches, France 12 4 13 Poincaré, Garches, France 14 5 15 Poincaré, Garches, France 16 6 EOH, Université Paris-Saclay, AP-HP Hôpital Raymond Poincaré, Garches, France 17 7 Pharmaco-toxicologie, Université Paris-Saclay, AP-HP Hôpital Raymond Poincaré, 18 Garches, France 19 8 20 Garches, France Maladies Infectieuses, Université Paris-Saclay, AP-HP Hôpital Raymond Poincaré, Rééducation fonctionnelle, Université Paris-Saclay, AP-HP Hôpital Raymond Pharmacie Hospitalière, Université Paris-Saclay, AP-HP Hôpital Raymond Réanimation médicale, Université Paris-Saclay, AP-HP Hôpital Raymond Poincaré, 21 22 Keywords: azithromycin, hydroxychloroquine, Covid-19, pneumonia 1 © 2020 published by Elsevier. This manuscript is made available under the Elsevier user license https://www.elsevier.com/open-access/userlicense/1.0/ 23 24 25 26 27 Corresponding author: 28 Benjamin Davido, Service de Maladies Infectieuses et Tropicales 29 Hôpital Raymond-Poincaré, Garches 92380, France. 30 Tel: +33-1-47107758, e-mail: benjamin.davido@aphp.fr 31 32 33 34 35 36 37 38 39 40 Abstract: 41 Introduction: Interest of anti-infective agents in COVD-19 showed discrepant results. 42 However, there is no evaluation about the impact in changes of practices on the 43 prognosis over time. 44 Methods: Single center, retrospective study, conducted from March 5th to April 25th 45 2020, in adults hospitalized in a medicine ward for a COVID-19. Patient 46 characteristics were compared between 2 periods (before/after March 19th) 47 considering French guidelines issued by learned societies. Aim of the study was to 2 48 evaluate how medical care impacted unfavorable outcome, namely admission in 49 intensive care unit (ICU) and/or death. 50 Results: One hundred thirty-two patients were admitted, mean age was 59.0 ± 16.3 51 years, 52 count<1000/mm3. When prescribed, anti-infective agents were lopinavir-ritonavir 53 (n=12), azithromycin (AZI) (n=28) and AZI combined with hydroxychloroquine (HCQ) 54 (n=52). Between the 2 periods we noted a significant decrease of ICU admission, 55 from 43% to 12% (p<0.0001). Delays until transfer in ICU were similar between 56 periods (p=0.86). Pulmonary CT-scan were significantly more performed (from 50% 57 to 90%, p<0.0001), as oxygen-dependency (53% vs 80%, p=0.001) and prescription 58 of AZI±HCQ (from 25% to 76%, p<0.0001) were greater over time. Multivariate 59 analyses showed a reduction of unfavorable outcome in patients receiving AZI±HCQ 60 (HR=0.45, 95%IC [0.21-0.97], p=0.04), especially among an identified category of 61 individuals (lymphocyte≥1000/mm3 or CRP≥100..
Late treatment
is less effective
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit